2025

2025

  • Registered U.S. patent for portable blood viscosity measurement kit06

2024

2024

  • Achieved annual sales of USD 4.1 billion12
  • Registered Japanese patent for multi-channel blood viscosity analyzer05
  • Received U.S. FDA approval for Rheovis 2000A and Rheovis 20004

2023

2023

  • Achieved annual sales of USD 1.6 billion12
  • Launched Rheovis 200 — medium-sized automated blood viscosity analyzer10
  • Received approval from MFDS (Korea) for Rheovis 2000A multi-channel automated analyzer04
  • Established Biorheologics Corporate R&D Center (No. 2023111078)02

2021

2021

  • Registered patent for multi-channel blood viscosity analyzer11

2019

2019

  • Certified as a venture company by KIBO (No. 20190107141)06
  • Established Biorheologics Co., Ltd.03